---
document_datetime: 2025-11-23 08:06:36
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-pfizer-previously-pemetrexed-hospira-uk-limited.html
document_name: pemetrexed-pfizer-previously-pemetrexed-hospira-uk-limited.html
version: success
processing_time: 0.1076565
conversion_datetime: 2025-12-28 11:21:03.482255
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Pemetrexed Pfizer (previously Pemetrexed Hospira UK Limited)

[RSS](/en/individual-human-medicine.xml/66799)

##### Withdrawn

This medicine's authorisation has been withdrawn

pemetrexed

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Pemetrexed Pfizer (previously Pemetrexed Hospira UK Limited)](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 26 April 2020, the marketing authorisation of Pemetrexed Pfizer (pemetrexed) ceased to be valid in the European Union (EU). The cessation of validity is due to the fact that the marketing authorisation holder, Pfizer Europe MA EEIG, had not marketed Pemetrexed Pfizer in the EU since its initial marketing authorisation.

In accordance with provisions of the sunset clause1, the marketing authorisation of the medicinal product lapsed as the product had not been marketed in any of the EU Member States within three years of its initial authorisation. Pfizer Europe MA EEIG confirmed that the product had not been marketed for commercial reasons.

Pemetrexed Pfizer was granted marketing authorisation in the EU on 26 April 2017 and was indicated

- in combination with cisplatin for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma and for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology;
- as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy and for the secondline treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

The marketing authorisation was initially valid for a 5-year period. Pemetrexed Pfizer is a generic medicine of Alimta. There are other generic medicinal products of Alimta authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Pemetrexed Pfizer is updated to indicate that the marketing authorisation is no longer valid.

Pemetrexed Hospira UK Limited : EPAR - Summary for the public

Reference Number: EMA/147008/2017

English (EN) (686.77 KB - PDF)

**First published:** 30/05/2017

**Last updated:** 28/07/2021

[View](/en/documents/overview/pemetrexed-hospira-uk-limited-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-913)

български (BG) (780.57 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/bg/documents/overview/pemetrexed-hospira-uk-limited-epar-summary-public_bg.pdf)

español (ES) (685.71 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/es/documents/overview/pemetrexed-hospira-uk-limited-epar-summary-public_es.pdf)

čeština (CS) (763.76 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/cs/documents/overview/pemetrexed-hospira-uk-limited-epar-summary-public_cs.pdf)

dansk (DA) (683.28 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/da/documents/overview/pemetrexed-hospira-uk-limited-epar-summary-public_da.pdf)

Deutsch (DE) (687.03 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/de/documents/overview/pemetrexed-hospira-uk-limited-epar-summary-public_de.pdf)

eesti keel (ET) (683.27 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/et/documents/overview/pemetrexed-hospira-uk-limited-epar-summary-public_et.pdf)

ελληνικά (EL) (786.77 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/el/documents/overview/pemetrexed-hospira-uk-limited-epar-summary-public_el.pdf)

français (FR) (686.43 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/fr/documents/overview/pemetrexed-hospira-uk-limited-epar-summary-public_fr.pdf)

hrvatski (HR) (706.19 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/hr/documents/overview/pemetrexed-hospira-uk-limited-epar-summary-public_hr.pdf)

italiano (IT) (684.54 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/it/documents/overview/pemetrexed-hospira-uk-limited-epar-summary-public_it.pdf)

latviešu valoda (LV) (708.59 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/lv/documents/overview/pemetrexed-hospira-uk-limited-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (711.19 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/lt/documents/overview/pemetrexed-hospira-uk-limited-epar-summary-public_lt.pdf)

magyar (HU) (755.98 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/hu/documents/overview/pemetrexed-hospira-uk-limited-epar-summary-public_hu.pdf)

Malti (MT) (763.67 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/mt/documents/overview/pemetrexed-hospira-uk-limited-epar-summary-public_mt.pdf)

Nederlands (NL) (685.02 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/nl/documents/overview/pemetrexed-hospira-uk-limited-epar-summary-public_nl.pdf)

polski (PL) (761.2 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/pl/documents/overview/pemetrexed-hospira-uk-limited-epar-summary-public_pl.pdf)

português (PT) (685.56 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/pt/documents/overview/pemetrexed-hospira-uk-limited-epar-summary-public_pt.pdf)

română (RO) (711.52 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/ro/documents/overview/pemetrexed-hospira-uk-limited-epar-summary-public_ro.pdf)

slovenčina (SK) (761.52 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/sk/documents/overview/pemetrexed-hospira-uk-limited-epar-summary-public_sk.pdf)

slovenščina (SL) (752.44 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/sl/documents/overview/pemetrexed-hospira-uk-limited-epar-summary-public_sl.pdf)

Suomi (FI) (683.54 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/fi/documents/overview/pemetrexed-hospira-uk-limited-epar-summary-public_fi.pdf)

svenska (SV) (684.85 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/sv/documents/overview/pemetrexed-hospira-uk-limited-epar-summary-public_sv.pdf)

## Product information

Pemetrexed Pfizer : EPAR - Product Information

English (EN) (419.85 KB - PDF)

**First published:** 30/05/2017

**Last updated:** 17/09/2025

[View](/en/documents/product-information/pemetrexed-pfizer-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-962)

български (BG) (802.46 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

17/09/2025

[View](/bg/documents/product-information/pemetrexed-pfizer-epar-product-information_bg.pdf)

español (ES) (807.77 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

17/09/2025

[View](/es/documents/product-information/pemetrexed-pfizer-epar-product-information_es.pdf)

čeština (CS) (1.03 MB - PDF)

**First published:**

30/05/2017

**Last updated:**

17/09/2025

[View](/cs/documents/product-information/pemetrexed-pfizer-epar-product-information_cs.pdf)

dansk (DA) (519.76 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

17/09/2025

[View](/da/documents/product-information/pemetrexed-pfizer-epar-product-information_da.pdf)

Deutsch (DE) (745.34 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

17/09/2025

[View](/de/documents/product-information/pemetrexed-pfizer-epar-product-information_de.pdf)

eesti keel (ET) (428.82 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

17/09/2025

[View](/et/documents/product-information/pemetrexed-pfizer-epar-product-information_et.pdf)

ελληνικά (EL) (477.55 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

17/09/2025

[View](/el/documents/product-information/pemetrexed-pfizer-epar-product-information_el.pdf)

français (FR) (500.99 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

17/09/2025

[View](/fr/documents/product-information/pemetrexed-pfizer-epar-product-information_fr.pdf)

hrvatski (HR) (527.91 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

17/09/2025

[View](/hr/documents/product-information/pemetrexed-pfizer-epar-product-information_hr.pdf)

íslenska (IS) (502.89 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

17/09/2025

[View](/is/documents/product-information/pemetrexed-pfizer-epar-product-information_is.pdf)

italiano (IT) (440.4 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

17/09/2025

[View](/it/documents/product-information/pemetrexed-pfizer-epar-product-information_it.pdf)

latviešu valoda (LV) (804.16 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

17/09/2025

[View](/lv/documents/product-information/pemetrexed-pfizer-epar-product-information_lv.pdf)

lietuvių kalba (LT) (453.46 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

17/09/2025

[View](/lt/documents/product-information/pemetrexed-pfizer-epar-product-information_lt.pdf)

magyar (HU) (641.48 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

17/09/2025

[View](/hu/documents/product-information/pemetrexed-pfizer-epar-product-information_hu.pdf)

Malti (MT) (531.59 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

17/09/2025

[View](/mt/documents/product-information/pemetrexed-pfizer-epar-product-information_mt.pdf)

Nederlands (NL) (563.55 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

17/09/2025

[View](/nl/documents/product-information/pemetrexed-pfizer-epar-product-information_nl.pdf)

norsk (NO) (449.81 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

17/09/2025

[View](/no/documents/product-information/pemetrexed-pfizer-epar-product-information_no.pdf)

polski (PL) (456.83 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

17/09/2025

[View](/pl/documents/product-information/pemetrexed-pfizer-epar-product-information_pl.pdf)

português (PT) (1.25 MB - PDF)

**First published:**

30/05/2017

**Last updated:**

17/09/2025

[View](/pt/documents/product-information/pemetrexed-pfizer-epar-product-information_pt.pdf)

română (RO) (557.49 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

17/09/2025

[View](/ro/documents/product-information/pemetrexed-pfizer-epar-product-information_ro.pdf)

slovenčina (SK) (558.12 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

17/09/2025

[View](/sk/documents/product-information/pemetrexed-pfizer-epar-product-information_sk.pdf)

slovenščina (SL) (752 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

17/09/2025

[View](/sl/documents/product-information/pemetrexed-pfizer-epar-product-information_sl.pdf)

Suomi (FI) (493.46 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

17/09/2025

[View](/fi/documents/product-information/pemetrexed-pfizer-epar-product-information_fi.pdf)

svenska (SV) (817.51 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

17/09/2025

[View](/sv/documents/product-information/pemetrexed-pfizer-epar-product-information_sv.pdf)

21/10/2020

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Pemetrexed Pfizer : EPAR - All Authorised presentations

English (EN) (596.99 KB - PDF)

**First published:** 30/05/2017

**Last updated:** 28/07/2021

[View](/en/documents/all-authorised-presentations/pemetrexed-pfizer-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-415)

български (BG) (623.33 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/bg/documents/all-authorised-presentations/pemetrexed-pfizer-epar-all-authorised-presentations_bg.pdf)

español (ES) (596.17 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/es/documents/all-authorised-presentations/pemetrexed-pfizer-epar-all-authorised-presentations_es.pdf)

čeština (CS) (613.24 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/cs/documents/all-authorised-presentations/pemetrexed-pfizer-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (598.54 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/da/documents/all-authorised-presentations/pemetrexed-pfizer-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (601.62 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/de/documents/all-authorised-presentations/pemetrexed-pfizer-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (596.08 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/et/documents/all-authorised-presentations/pemetrexed-pfizer-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (623.36 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/el/documents/all-authorised-presentations/pemetrexed-pfizer-epar-all-authorised-presentations_el.pdf)

français (FR) (595.38 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/fr/documents/all-authorised-presentations/pemetrexed-pfizer-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (597.42 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/hr/documents/all-authorised-presentations/pemetrexed-pfizer-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (595.57 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/is/documents/all-authorised-presentations/pemetrexed-pfizer-epar-all-authorised-presentations_is.pdf)

italiano (IT) (596.47 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/it/documents/all-authorised-presentations/pemetrexed-pfizer-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (614.9 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/lv/documents/all-authorised-presentations/pemetrexed-pfizer-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (595.81 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/lt/documents/all-authorised-presentations/pemetrexed-pfizer-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (613.28 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/hu/documents/all-authorised-presentations/pemetrexed-pfizer-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (617.01 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/mt/documents/all-authorised-presentations/pemetrexed-pfizer-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (596.24 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/nl/documents/all-authorised-presentations/pemetrexed-pfizer-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (597.38 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/no/documents/all-authorised-presentations/pemetrexed-pfizer-epar-all-authorised-presentations_no.pdf)

polski (PL) (614.07 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/pl/documents/all-authorised-presentations/pemetrexed-pfizer-epar-all-authorised-presentations_pl.pdf)

português (PT) (608.59 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/pt/documents/all-authorised-presentations/pemetrexed-pfizer-epar-all-authorised-presentations_pt.pdf)

română (RO) (596.53 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/ro/documents/all-authorised-presentations/pemetrexed-pfizer-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (614.22 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/sk/documents/all-authorised-presentations/pemetrexed-pfizer-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (610.77 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/sl/documents/all-authorised-presentations/pemetrexed-pfizer-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (596.45 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/fi/documents/all-authorised-presentations/pemetrexed-pfizer-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (596.43 KB - PDF)

**First published:**

30/05/2017

**Last updated:**

28/07/2021

[View](/sv/documents/all-authorised-presentations/pemetrexed-pfizer-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Pemetrexed Pfizer (previously Pemetrexed Hospira UK Limited) Active substance pemetrexed ditromethamine International non-proprietary name (INN) or common name pemetrexed Therapeutic area (MeSH)

- Carcinoma, Non-Small-Cell Lung
- Mesothelioma

Anatomical therapeutic chemical (ATC) code L01BA04

### Pharmacotherapeutic group

- ANTIMETABOLITES
- Folic acid analogues

### Therapeutic indication

**Malignant pleural mesothelioma**

Pemetrexed Hospira UK Limited in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.

**Non-small cell lung cancer**

Pemetrexed Hospira UK Limited in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see SmPC section 5.1).

Pemetrexed Hospira UK Limited is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see SmPC section 5.1).

Pemetrexed Hospira UK Limited is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see SmPC section 5.1).

## Authorisation details

EMA product number EMEA/H/C/004488

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

Opinion adopted 23/02/2017 Marketing authorisation issued 24/04/2017 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Pemetrexed Pfizer : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (683.5 KB - PDF)

**First published:** 06/02/2018

**Last updated:** 28/07/2021

[View](/en/documents/procedural-steps-after/pemetrexed-pfizer-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Pemetrexed Hospira UK Limited : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/270680/2017

English (EN) (988.58 KB - PDF)

**First published:** 30/05/2017

**Last updated:** 28/07/2021

[View](/en/documents/assessment-report/pemetrexed-hospira-uk-limited-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Pemetrexed Hospira UK Limited

Adopted

Reference Number: EMA/CHMP/96855/2017

English (EN) (704.98 KB - PDF)

**First published:** 24/02/2017

**Last updated:** 29/07/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-pemetrexed-hospira-uk-limited_en.pdf)

#### News on Pemetrexed Pfizer (previously Pemetrexed Hospira UK Limited)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 February 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-february-2017) 24/02/2017

**This page was last updated on** 29/07/2021

## Share this page

[Back to top](#main-content)